Copyright (c) 2010 Yahoo! Inc. All rights reserved.http://finance.yahoo.com/q/h?s=emis.obLatest Financial News for EMISPHERE TECHen-usMon, 21 Dec 2009 14:00:00 Etc/GMThttp://us.news2.yimg.com/us.yimg.com/p/fi/pr/40197.gifhttp://finance.yahoo.com14417http://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091221/20091221005057.html?.v=1CEDAR KNOLLS, N.J.----Emisphere Technologies, Inc. today announced a meta-analysis published in the December 2009 edition of Rheumatology Reports examining independent evidence of the analgesic action of the hormone calcitonin.yahoo_finance/2438317604Mon, 21 Dec 2009 14:00:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091210/20091210005582.html?.v=1CEDAR KNOLLS, N.J.----Emisphere Technologies, Inc. today announced that an independent Data Monitoring Committee informed Novartis and its partner Nordic Bioscience about their recommendation to proceed with the Osteoporosis Phase 3 Study 2303 and the Osteoarthritis Phase 3 Study 2301 exploring the safety and efficacy of an oral formulation of salmon calcitonin to treat patients with osteoporosis and osteoarthritis of the knee.yahoo_finance/182076519Thu, 10 Dec 2009 15:07:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091130/emis.ob8-k.htmlyahoo_finance/778336239Mon, 30 Nov 2009 18:40:42 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091130/20091130005458.html?.v=1CEDAR KNOLLS, N.J.----Emisphere Technologies, Inc. , a biopharmaceutical company that focuses on a unique and improved delivery of pharmaceutical compounds and nutritional supplements using its Eligen® Technology, today announced that Novartis Pharma AG has agreed to extend the maturity date of Emisphere’s Convertible Promissory Note to February 26, 2010.yahoo_finance/4046854681Mon, 30 Nov 2009 13:45:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091124/20091124005260.html?.v=1CEDAR KNOLLS, N.J.----Emisphere Technologies, Inc. , a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules and pharmaceutical compounds using its Eligen® Technology, today announced that President and Chief Executive Officer, Michael V.yahoo_finance/3559870220Tue, 24 Nov 2009 14:05:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091120/20091120005709.html?.v=1NEW YORK----The New York Society of Security Analysts will present the 13th Annual Biotech and Specialty Pharmaceuticals Conference on December 1, 2009.yahoo_finance/3791627478Fri, 20 Nov 2009 20:02:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091116/emis.ob8-k.htmlyahoo_finance/864312663Mon, 16 Nov 2009 21:16:04 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://finance.yahoo.com/q/is?s=emis.obyahoo_finance/2914384991Fri, 13 Nov 2009 14:05:24 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091109/emis.ob8-k.htmlyahoo_finance/1799399263Mon, 9 Nov 2009 14:02:54 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091109/20091109005233.html?.v=1CEDAR KNOLLS, N.J.----Emisphere Technologies, Inc. today announced financial and operational results for the third quarter and nine months ended September 30, 2009.yahoo_finance/1848784442Mon, 9 Nov 2009 13:45:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/research/earncal/20091109.html?t=emisyahoo_finance/3432261410Mon, 9 Nov 2009 12:07:25 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091106/emis.ob8-k.htmlyahoo_finance/4139537392Fri, 6 Nov 2009 11:02:50 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091105/20091105006512.html?.v=1CEDAR KNOLLS, N.J.----Emisphere Technologies, Inc. today announced that Tim Rothwell, former Chairman of Sanofi-aventis U.S., has been appointed to the Company’s Board of Directors effective immediately.yahoo_finance/1817636783Thu, 5 Nov 2009 21:29:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091104/20091104005112.html?.v=1yahoo_finance/2172738840Wed, 4 Nov 2009 13:45:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091102/20091102006404.html?.v=1CEDAR KNOLLS, N.J.----Emisphere Technologies, Inc. today announced that interim data from an ongoing study demonstrated its high-dose oral Eligen® B12 performed as well as or better than B12 injections in individuals with Vitamin B12 deficiency.yahoo_finance/2145159365Mon, 2 Nov 2009 21:07:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091029/emis.ob8-k.htmlyahoo_finance/1291896744Thu, 29 Oct 2009 20:16:06 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091021/emis.ob10-q_a.htmlyahoo_finance/4032433721Wed, 21 Oct 2009 21:21:57 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/e/091020/emis.ob8-k.htmlyahoo_finance/1597216201Tue, 20 Oct 2009 21:05:01 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091020/20091020006033.html?.v=1CEDAR KNOLLS, N.J.----Emisphere Technologies, Inc. today announced study results demonstrating that a single dose of the novel oral parathyroid hormone PTH1-34, which utilizes Emisphere’s proprietary Eligen® Drug Delivery Technology and absorption-enhancer carrier molecule 5-CNAC, achieved potentially therapeutically relevant exposure and safety profiles to those of the currently available injectable formulation in healthy postmenopausal women.yahoo_finance/3816678425Tue, 20 Oct 2009 13:39:00 Etc/GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/091015/20091015005584.html?.v=1yahoo_finance/4125634775Thu, 15 Oct 2009 13:30:00 Etc/GMT